Dr. Eric K. Singhi

Expert oncologists Dr. Joshua K. Sabari and Dr. Eric K. Singhi break down key updates and takeaways in lung cancer treatment following ASCO 2025.

Bringing Light to More Personalized Medicine in Lung Cancer After ASCO 2025

During the 2025 ASCO Annual Meeting, key updates were shared across all of oncology, including across lung cancer care. These updates are important for patients to learn more about, as these new data are driving the future of their care and changing the standards in which they are treated.

Expert oncologists, Dr. Joshua K. Sabari and Dr. Eric K. Singhi, sat down to discuss these updates and share their thoughts on how this affects patients and caregivers in an interview hosted by Singhi.

Singhi, an assistant professor in the Department of General Oncology and the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, kicked off the conversation by discussing key outcomes from the CheckMate 816 trial; five-year overall survival updates from the study were shared at the meeting.

The trial evaluated treatment with a combination of chemotherapy plus immunotherapy given before surgery compared with chemotherapy alone before surgery. What investigators found is that patients who were treated with the combination of chemotherapy and immunotherapy before surgery benefited most compared with those who did not receive the investigative treatment. Moreover, at the five-year update, 65% of patients were still alive when treated with the investigative regimen compared with 55% of patients alive who had chemotherapy alone before surgery.

"Whenever a patient goes gets their tumor removed, after surgery, we look under the microscope, and we look to see how many cancer cells are still alive. What we saw was that in patients that got chemotherapy and immunotherapy together before surgery, there was a higher chance of having no living cancer cells still there at the time of surgery. So that was really important," Singhi explained in the interview.

Moreover, Sabari went on to ask Singhi about the treatment of patients with non-small cell lung cancer (NSCLC) whose disease has a KRAS G12c mutation; patients with this mutation make up approximately 30% of all NSCLCs. Singhi responded by saying that the big question in this patient population is to see if some of these targeted therapies can be moved into earlier stages of treatment.

The pair concluded by calling for more actionable, phase 3 data where an experimental treatment is tested versus a control arm.

Transcript has been edited for clarity and conciseness.

For more news on cancer updates, research and education,

don’t forget to subscribe to CURE®’s newsletters here.

Videos

"Her compassion, expertise and commitment to personalized patient care for patients make her a shining beacon of hope and healing for those battling lung cancer."

It is with great pleasure that I nominate Amy Wallace, RN, OCN, an exceptional oncology nurse at The University of Texas MD Anderson Cancer Center in Houston, for the Extraordinary Healer Award. Amy has dedicated her life to providing compassionate care and support to patients with lung cancer, embodying the qualities of empathy, expertise and dedication.

As a practicing thoracic medical oncologist at The University of Texas MD Anderson Cancer Center, I have known Amy for two years now as my primary nurse in my thoracic medical oncology clinic. Together, we have cared for hundreds of patients with lung cancer and their families who are not only from the state of Texas, but also travel from other national and international locations to meet with us.

What sets Amy apart is her profound understanding of the challenges faced by patients with cancer, as she has personally experienced the impact of this disease within her own family. Having lost a family member to cancer, she channels this poignant experience into her work, fostering a deep connection with her patients and their loved ones. This unique empathy creates a comforting and understanding environment, helping patients feel heard and supported.

Amy is renowned for her calming presence, which becomes immediately apparent when patients meet her. Many of our patients and their loves ones are understandably anxious at our initial medical oncology visit. Amy’s ability to instill a sense of peace and reassurance is invaluable, especially in the challenging journey that is a cancer diagnosis. Patients often express how her comforting demeanor has a positive impact on their overall well-being. They look forward to not only meeting with me at follow-up visits but also Amy.

Furthermore, Amy goes above and beyond to personalize the scheduling of appointments for her patients. Recognizing the significance of maximizing quality of life and minimizing time spent at our cancer center, she tailors their schedules with meticulous attention to detail. This thoughtful approach showcases her commitment to enhancing the overall patient experience.

In preparation for patient visits, Amy demonstrates exceptional dedication. Her thorough preparation ensures that each patient receives personalized and effective care. Moreover, her commitment extends beyond the clinic as she diligently follows up with patients, ensuring they feel supported and addressing any concerns that may arise post-appointment as they continue through their cancer treatment journey.

What truly sets Amy apart is her team approach to patient care. She collaborates seamlessly with other health care professionals, as the care of a patient with lung cancer is very heavily focused on multidisciplinary care, fostering an environment of comprehensive support for patients and their families. This collaborative spirit enhances the overall effectiveness of the care provided and reinforces the sense of community within the health care team.

. Her compassion, expertise and commitment to personalized patient care for patients make her a shining beacon of hope and healing for those battling lung cancer.

I am honored to nominate Amy Wallace, RN, an oncology nurse at The University of Texas MD Anderson Cancer Center in Houston, for the CURE Extraordinary Healer award. Amy embodies the essence of exceptional nursing care, compassion and dedication to her patients and colleagues. With over a decade of experience in oncology, she has developed a unique expertise in cancer care, providing individualized attention to each patient’s physical and emotional needs. Her unwavering empathy and kindness create a safe and supportive environment for patients and their families during their most vulnerable moments.

Amy’s exceptional clinical skills are complemented by her leadership and mentorship. She actively participates in professional development, staying updated on the latest cancer treatments and best practices. She eagerly shares her knowledge with colleagues, fostering a collaborative work environment that benefits patients and staff alike. Her tireless advocacy for patients extends beyond the bedside, driving improvements in cancer care policies and protocols.

I strongly believe that Amy deserves recognition with the CURE Extraordinary Healer award for her outstanding contributions to the nursing profession and her unwavering commitment to cancer care. She is an inspiration for everyone, but especially for me. I look up to her to become an extraordinary, caring, kind and devoted nurse like Amy. I wish everyone could have a nurse like Amy. She is a wonderful nurse.

For more news on cancer updates, research and education, don’t forget to 

subscribe to CURE®’s newsletters here.

Articles

Two colleagues of Amy Wallace, an oncology nurse, nominated her for the Extraordinary Healer Award based on her care of patients with lung cancer.

Dr. Eric K. Singhi

Bringing Light to More Personalized Medicine in Lung Cancer After ASCO 2025

Guiding Hope for Patients With Lung Cancer

Latest News